TREATMENT OUTCOMES AND PROGNOSTIC FACTORS IN HEAD AND NECK MALIGNANCIES

ABSTRACT

Head and neck malignancies comprise a heterogeneous group of tumors arising from the mucosal surfaces of the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, salivary glands, and other anatomical structures. They represent the seventh most common cancer worldwide, accounting for more than 900,000 new cases and approximately 450,000 deaths annually. Despite remarkable advances in surgical techniques, radiotherapy, systemic chemotherapy, targeted therapy, and immunotherapy, treatment outcomes remain highly variable due to differences in tumor biology, disease stage, molecular characteristics, and patient-related factors. The increasing prevalence of human papillomavirus (HPV)-associated oropharyngeal carcinoma has significantly altered the epidemiological landscape and prognosis of head and neck cancers, whereas Epstein–Barr virus (EBV)-associated nasopharyngeal carcinoma continues to represent a distinct biological entity with unique therapeutic considerations.

Keywords: head and neck cancer; squamous cell carcinoma; prognosis; treatment outcomes; survival; immunotherapy; biomarkers; HPV; EBV.

Head and neck malignancies encompass a diverse spectrum of neoplasms originating from the upper aerodigestive tract, including cancers of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, sinonasal tract, and salivary glands. More than 90% of these tumors are classified as head and neck squamous cell carcinoma (HNSCC), making it one of the most extensively investigated solid malignancies worldwide [1, 2].

Globally, head and neck cancer remains a significant public health challenge because of its high incidence, considerable mortality, and profound impact on speech, swallowing, respiration, nutrition, and psychosocial well-being. According to GLOBOCAN 2022 estimates, head and neck cancers account for nearly one million newly diagnosed cases annually, with incidence rates continuing to increase in many countries due to changing demographic patterns and the growing burden of HPV-associated disease [3].

Traditionally, tobacco smoking and excessive alcohol consumption have been considered the principal etiological factors for HNSCC. However, over the past two decades, persistent infection with high-risk human papillomavirus, particularly HPV-16, has emerged as a dominant risk factor for oropharyngeal carcinoma. Patients with HPV-positive tumors generally demonstrate superior responses to radiotherapy and chemotherapy, significantly improved overall survival, and lower recurrence rates compared with HPV-negative disease [4].

Similarly, Epstein-Barr virus remains strongly associated with endemic nasopharyngeal carcinoma, especially in East and Southeast Asia. Advances in EBV DNA monitoring have considerably improved early diagnosis, prognostic stratification, and post-treatment surveillance of these patients [5].

Management of head and neck malignancies has evolved substantially over recent decades through multidisciplinary collaboration involving surgeons, radiation oncologists, medical oncologists, radiologists, pathologists, nutrition specialists, rehabilitation physicians, speech therapists, and palliative care teams. Modern treatment strategies include minimally invasive surgery, transoral robotic surgery (TORS), intensity-modulated radiotherapy (IMRT), proton therapy, concurrent chemoradiotherapy, molecular-targeted agents such as cetuximab, and immune checkpoint inhibitors including pembrolizumab and nivolumab [6-9].

Although these therapeutic advances have improved locoregional control and overall survival, treatment outcomes remain heterogeneous. Clinical prognosis depends on numerous interacting variables including tumor stage, anatomical location, pathological differentiation, surgical margin status, extranodal extension, lymphovascular invasion, perineural invasion, HPV or EBV status, molecular biomarkers, host immune response, nutritional status, comorbidities, and treatment adherence [10].

Conclusion

Head and neck malignancies remain a major global oncological challenge because of their biological heterogeneity and complex impact on patient function and quality of life. Treatment outcomes have improved substantially with advances in surgery, IMRT, systemic therapy, targeted therapy, and immunotherapy. Nevertheless, prognosis is determined by a multifactorial interplay of tumor stage, viral status, pathological features, molecular biomarkers, and patient-related characteristics.

References:

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
2. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3
3. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269-282. doi: 10.1038/nrc.2018.11
4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi: 10.1056/NEJMoa0912217
5. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence. J Clin Oncol. 2011;29(32):4294-4301. doi: 10.1200/JCO.2011.36.4596
6. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2024.
8. Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer. Radiother Oncol. 2009;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014
9. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11. J Clin Oncol. 2013;31(7):845-852. doi: 10.1200/JCO.2012.43.6097
10. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients. Nat Clin Pract Oncol. 2005;2(3):156-157. doi: 10.1038/ncponc0110